These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein. Marksteiner J; Hinterhuber H; Humpel C Drugs Today (Barc); 2007 Jun; 43(6):423-31. PubMed ID: 17612711 [TBL] [Abstract][Full Text] [Related]
4. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic. Shea YF; Ha J; Chu LW Psychogeriatrics; 2015 Dec; 15(4):235-41. PubMed ID: 25533477 [TBL] [Abstract][Full Text] [Related]
5. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia. Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675 [TBL] [Abstract][Full Text] [Related]
6. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia. Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease. Valcárcel-Nazco C; Perestelo-Pérez L; Molinuevo JL; Mar J; Castilla I; Serrano-Aguilar P J Alzheimers Dis; 2014; 42(3):777-88. PubMed ID: 24916543 [TBL] [Abstract][Full Text] [Related]
8. [Neurochemical markers of neurodegeneration in the early diagnosis of Alzheimer's disease, vascular and mixed dementia]. Uspenskaia OV; Iakhno NN; Belushkina NN Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(8):36-40. PubMed ID: 20823828 [TBL] [Abstract][Full Text] [Related]
9. Toward an early diagnosis and treatment of Alzheimer's disease. Nordberg A Int Psychogeriatr; 2003 Sep; 15(3):223-37. PubMed ID: 14756159 [TBL] [Abstract][Full Text] [Related]
16. Applied multimodal diagnostics in a case of presenile dementia. Schönecker S; Brendel M; Huber M; Vollmar C; Huppertz HJ; Teipel S; Okamura N; Levin J; Rominger A; Danek A BMC Neurol; 2016 Aug; 16():131. PubMed ID: 27506761 [TBL] [Abstract][Full Text] [Related]
17. Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting. Perani D; Cerami C; Caminiti SP; Santangelo R; Coppi E; Ferrari L; Pinto P; Passerini G; Falini A; Iannaccone S; Cappa SF; Comi G; Gianolli L; Magnani G Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):499-508. PubMed ID: 26341365 [TBL] [Abstract][Full Text] [Related]
18. Supportive CSF biomarker evidence to enhance the National Institute on Aging-Alzheimer's Association criteria for diagnosis of Alzheimer's type dementia--a study from Southern India. Huded CB; Bharath S; Chandra SR; Sivakumar PT; Varghese M; Subramanian S Asian J Psychiatr; 2015 Feb; 13():44-7. PubMed ID: 25468261 [TBL] [Abstract][Full Text] [Related]
19. A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium. Somers C; Struyfs H; Goossens J; Niemantsverdriet E; Luyckx J; De Roeck N; De Roeck E; De Vil B; Cras P; Martin JJ; De Deyn PP; Bjerke M; Engelborghs S J Alzheimers Dis; 2016 Aug; 54(1):383-95. PubMed ID: 27567807 [TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia. Nägga K; Gottfries J; Blennow K; Marcusson J Dement Geriatr Cogn Disord; 2002; 14(4):183-90. PubMed ID: 12411760 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]